All In Biotech

Investigational drug · Phase 3

atropine sulfate eye drops

Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Myopia, Myopia Progression.

Phase 3

Last checked: Nov 20, 2026Latest source record: Jan 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

3

3 still active

All registered trials

91

Any phase or sponsor naming "atropine sulfate eye drops"

First trial start

2022

Mar 15, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "atropine sulfate eye drops", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Myopia
  • Myopia Progression

Largest trials

Live from ClinicalTrials.gov: studies naming "atropine sulfate eye drops" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 14 on PubMed

Also in development for Myopia

  • Lower sulfate eye dropsLower sulfatePhase 32 trials

    Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. · Myopia

  • CTO0308Phase 31 trial

    Taejoon Pharmaceutical Co., Ltd. · Myopia

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.